Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Frédéric E. Lecouvet, Daniela E. Oprea-Lager, Yan Liu, Piet Ost, Luc Bidaut, Laurence Collette, Christophe M. Deroose, Karolien Goffin, Ken Herrmann, Otto S. Hoekstra, Gem Kramer, Yolande Lievens, Egesta Lopci, David Pasquier, Lars J. Petersen, Jean Noël Talbot, Helle Zacho, Bertrand Tombal, Nandita M. deSouza

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.

Original languageEnglish
Pages (from-to)e534-e545
JournalThe Lancet Oncology
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Prostatic Neoplasms
Organizations
Neoplasm Metastasis
Research
Neoplasms
Therapeutics
Diffusion Magnetic Resonance Imaging
Castration
Choline
Clinical Trials
Guidelines
Ligands
Morbidity
Recurrence

ASJC Scopus subject areas

  • Oncology

Cite this

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer : a consensus recommendation from the EORTC Imaging Group. / Lecouvet, Frédéric E.; Oprea-Lager, Daniela E.; Liu, Yan; Ost, Piet; Bidaut, Luc; Collette, Laurence; Deroose, Christophe M.; Goffin, Karolien; Herrmann, Ken; Hoekstra, Otto S.; Kramer, Gem; Lievens, Yolande; Lopci, Egesta; Pasquier, David; Petersen, Lars J.; Talbot, Jean Noël; Zacho, Helle; Tombal, Bertrand; deSouza, Nandita M.

In: The Lancet Oncology, Vol. 19, No. 10, 01.10.2018, p. e534-e545.

Research output: Contribution to journalReview article

Lecouvet, FE, Oprea-Lager, DE, Liu, Y, Ost, P, Bidaut, L, Collette, L, Deroose, CM, Goffin, K, Herrmann, K, Hoekstra, OS, Kramer, G, Lievens, Y, Lopci, E, Pasquier, D, Petersen, LJ, Talbot, JN, Zacho, H, Tombal, B & deSouza, NM 2018, 'Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group', The Lancet Oncology, vol. 19, no. 10, pp. e534-e545. https://doi.org/10.1016/S1470-2045(18)30571-0
Lecouvet, Frédéric E. ; Oprea-Lager, Daniela E. ; Liu, Yan ; Ost, Piet ; Bidaut, Luc ; Collette, Laurence ; Deroose, Christophe M. ; Goffin, Karolien ; Herrmann, Ken ; Hoekstra, Otto S. ; Kramer, Gem ; Lievens, Yolande ; Lopci, Egesta ; Pasquier, David ; Petersen, Lars J. ; Talbot, Jean Noël ; Zacho, Helle ; Tombal, Bertrand ; deSouza, Nandita M. / Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer : a consensus recommendation from the EORTC Imaging Group. In: The Lancet Oncology. 2018 ; Vol. 19, No. 10. pp. e534-e545.
@article{62e21336084c44238404229b1659301b,
title = "Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group",
abstract = "Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.",
author = "Lecouvet, {Fr{\'e}d{\'e}ric E.} and Oprea-Lager, {Daniela E.} and Yan Liu and Piet Ost and Luc Bidaut and Laurence Collette and Deroose, {Christophe M.} and Karolien Goffin and Ken Herrmann and Hoekstra, {Otto S.} and Gem Kramer and Yolande Lievens and Egesta Lopci and David Pasquier and Petersen, {Lars J.} and Talbot, {Jean No{\"e}l} and Helle Zacho and Bertrand Tombal and deSouza, {Nandita M.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/S1470-2045(18)30571-0",
language = "English",
volume = "19",
pages = "e534--e545",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer

T2 - a consensus recommendation from the EORTC Imaging Group

AU - Lecouvet, Frédéric E.

AU - Oprea-Lager, Daniela E.

AU - Liu, Yan

AU - Ost, Piet

AU - Bidaut, Luc

AU - Collette, Laurence

AU - Deroose, Christophe M.

AU - Goffin, Karolien

AU - Herrmann, Ken

AU - Hoekstra, Otto S.

AU - Kramer, Gem

AU - Lievens, Yolande

AU - Lopci, Egesta

AU - Pasquier, David

AU - Petersen, Lars J.

AU - Talbot, Jean Noël

AU - Zacho, Helle

AU - Tombal, Bertrand

AU - deSouza, Nandita M.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.

AB - Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.

UR - http://www.scopus.com/inward/record.url?scp=85054099763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054099763&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30571-0

DO - 10.1016/S1470-2045(18)30571-0

M3 - Review article

C2 - 30303127

AN - SCOPUS:85054099763

VL - 19

SP - e534-e545

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -